John Wilson departed as director at Kalaris Therapeutics, Inc..
“on March 29, 2022, John Wilson notified the Board that he will be retiring from the Board and will not stand for re-election at AlloVir’s 2022 annual meeting of shareholders.”
Kalaris Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from Kalaris Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Shawn Tomasello was appointed as director at Kalaris Therapeutics, Inc..
“On March 29, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of AlloVir, Inc. (“AlloVir”), the Board appointed Shawn Tomasello to the Board, effectively immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.